Osteoporosis Follow-Up Program for Private Clinics in Egypt: From Fracture to Treatment
Short answer: An osteoporosis follow-up program for a private clinic in Egypt is a registry of patients with fragility fractures or high fracture risk, with a recall for bone-density testing, a documented treatment decision after every fracture, and regular adherence checks. Its purpose is to close the gap between the fracture and the first treatment.
Key takeaways
- A multi-centre Egyptian study of 236 patients admitted with osteoporotic fractures found that 82.1% of eligible postmenopausal women and all eligible men were on no osteoporosis therapy.
- The authors link that gap mainly to low rates of diagnosis and inadequate patient education, which are both process problems a clinic can measure.
- Hip fracture incidence in Egypt was reported at 123.34 per 100,000 women and 55.19 per 100,000 men, with higher incidence in the south than the north.
- A fracture should open a care pathway: risk assessment, bone-density test, treatment decision, then recall.
- The program supports the physician; it does not choose drugs or intervals.

On this page
Why osteoporosis follow-up is an operations problem
Osteoporosis is silent until a bone breaks. In Egypt, the treatment gap after that first fracture is the part a clinic can see. In the 2023 multi-centre study by El Miedany and colleagues in Archives of Osteoporosis, men and postmenopausal women admitted with osteoporotic fractures were assessed for fracture risk, falls and sarcopenia and offered DXA. Of those eligible for therapy, 82.1% of postmenopausal women and 100% of men received no osteoporosis therapy. The authors point to under-diagnosis and inadequate education as the main drivers and note that Egypt's recent guidelines endorse a fracture-centric approach.
For a private clinic, that is a practical question: after a patient with a wrist, spine or hip fracture leaves the orthopaedic or emergency pathway, who owns the next step? Too often nobody does, because the fracture is treated and the bone is not.
What the Egyptian evidence tells clinic owners
Incidence is measurable and varies by region
The Egyptian Academy of Bone Health reported hip fracture incidence of 123.34 per 100,000 in women and 55.19 per 100,000 in men from two fracture liaison service centres between 2022 and 2023, higher in the south (113.62) than in the north (64.8), with different risk-factor patterns. The paper is an incidence study, not a statement about any one clinic, but it shows why local data matter.
The cost of a hip fracture is large
An Egyptian cost analysis combining national estimates with data from three fracture liaison service centres counted 412 patients with osteoporotic hip fractures. It reported that none of the patients was on osteoporosis therapy, a post-surgery mortality of 4.5%, and an estimated first-year direct surgical cost of about EGP 1.97 billion, based on official tariffs. The authors note that private-sector costs are excluded, and that only 141 of 412 patients had BMD measured. For a clinic, the second number is the more actionable one: if the bone-density test is missing, the diagnosis is too.
Designing the program: six components
1. A registry with a clear enrolment trigger. Enrol on a fragility fracture (wrist, vertebra, hip, humerus), a DXA result in the osteoporotic range, or long-term steroid use, whichever comes first. One patient, one record.
2. A fracture-risk and falls record. The Egyptian studies used FRAX, falls and sarcopenia assessments. The treating physician chooses the tools and makes them structured fields.
3. A DXA and bone-profile recall. Many patients are told to "do a DXA" and never do. The registry should show who has a pending test and recall them through the channel they actually answer, usually a phone call or WhatsApp.
4. A treatment-decision record. After every fracture, the chart should show a documented decision: treat, defer with reason, or refer. The doctor decides; the system makes the question visible. See also high cholesterol follow-up for private clinics for the same recall logic applied to lipids.
5. Adherence and persistence checks. Osteoporosis medicines are long-term. Track the refill or next-injection date, side-effect reports and missed reviews. The approach in warfarin and INR follow-up shows how a due-date worklist keeps a long-term treatment from lapsing.
6. Patient and family education. Because the Egyptian authors cite inadequate education, build a short Arabic education sequence on falls prevention, calcium and vitamin D questions to ask the doctor, and why the test and the treatment matter. The doctor reviews the content.
An illustrative scenario
Consider a private orthopaedic and rheumatology clinic in Nasr City (an illustrative example, not a customer case). A 68-year-old woman is treated for a wrist fracture after a fall at home and goes back to normal life. Without a program, nothing follows. With the program, the fracture enrols her, the registry flags the missing DXA, a nurse calls her and her daughter, the doctor reviews the result, records a decision, and the next review is booked. If she is prescribed a long-term treatment, her refill dates appear on the same list. Nothing about the clinical decision changes; what changes is that it is made, recorded and followed.
Metrics worth reporting
Share of fracture patients with a DXA recorded within the interval set by the physician; share with a documented treatment decision; share on treatment at last review; refill or persistence gap alerts raised and resolved; recall success rate; share with a falls assessment. Report these as operational measures, and show the number lost to follow-up beside them.
Governance and data protection
An osteoporosis registry contains sensitive health data. Define purpose, access roles and retention before launch, document patient consent for reminders, and decide where data are hosted. Confirm requirements under Egypt's Personal Data Protection Law with your legal adviser.
Where a platform fits
A clinic platform such as CareSync Clinic can host the registry, worklists, reminders and dashboards while the clinic's own record remains the source for diagnoses and prescriptions. Start with one pathway: fracture patients over 50. For adjacent women's-health follow-up, see PCOS follow-up for private clinics.
Frequently asked questions
What is an osteoporosis follow-up program? A structured pathway that registers patients with fragility fractures or high fracture risk, recalls them for bone-density testing, records a treatment decision and checks adherence over time, coordinated with the treating physician.
How big is the osteoporosis treatment gap in Egypt? In a 2023 multi-centre study of 236 patients with osteoporotic fractures, 82.1% of eligible postmenopausal women and 100% of eligible men received no osteoporosis therapy (El Miedany et al.). A single study does not describe every clinic, so measure your own.
Who should be in an osteoporosis registry? Patients with a fragility fracture, an osteoporotic DXA result, or another risk factor the physician defines, such as long-term steroid use.
Does a follow-up program decide treatment? No. The physician chooses tests, drugs and intervals. The program makes sure the decision is made, recorded and followed up.
How can a clinic protect patient data in a registry? Role-based access, documented consent for reminders, neutral message wording and a data-protection review before launch.
Sources (retrieved through search on 22 November 2026; only abstracts or open pages were read):
- El Miedany Y, et al. Osteoporosis treatment gap in patients at risk of fracture in Egypt: a multi-center, cross-sectional observational study. Archives of Osteoporosis, 2023:
- El Miedany Y, et al. Incidence and geographic characteristics of the population with osteoporotic hip fracture in Egypt. Archives of Osteoporosis, 2023:
- El Miedany Y, et al. Health economics: direct cost of osteoporotic hip fracture in Egypt. Egyptian Rheumatology and Rehabilitation, 2023: